Revenue (Tables)

3 Months Ended

Mar. 31, 2022

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenues

Our disaggregated revenues were as follows (in thousands):

	Three Months Ended  March 31,
	2022		2021
Royalties	$	69,605	$	36,923
Product sales, net
Sales of bulk rHuPH20	$	16,448	$	16,770
Sales of Hylenex	5,692		4,996
Total product sales, net	$	22,140	$	21,766
Revenues under collaborative agreements:
Upfront license and target nomination fees	$	25,000	$	—
Event-based development and regulatory milestones and other fees	—		30,000
Reimbursement for research and development services	534		333
Total revenues under collaborative agreements	$	25,534	$	30,333
Total revenue	$	117,279	$	89,022

Schedule of accounts receivable, deferred revenues from contracts with customers, and amounts under collaborative agreements included in transaction price

Accounts receivable, net, and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):

	March 31, 2022		December 31, 2021
Accounts receivable, net	$	113,762	$	90,975
Deferred revenues	3,777		4,276